<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00967187</url>
  </required_header>
  <id_info>
    <org_study_id>MPC-4326-204</org_study_id>
    <secondary_id>BVM Study 204</secondary_id>
    <nct_id>NCT00967187</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of MPC-4326 for Treatment of Patients With HIV-1 Infection.</brief_title>
  <official_title>A Phase II Multicenter, Open-label, Randomized, Parallel Group, Study of Bevirimat in HIV-1 Positive Patients to Evaluate the Safety, Efficacy, and Pharmacokinetics of MPC-4326 Administered as Monotherapy for 14 Days and as Part of an Optimized Background Regimen for up to 72 Weeks.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myrexis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Myrexis Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the antiretroviral activity and safety of 200 mg BID and 300 mg BID doses of
      MPC-4326 administered as monotherapy for 14 days to HIV-1 positive patients. Patients with an
      initial treatment response will have the option to continue MPC-4326 in combination with an
      Optimized Backround Regimen for a maximum of 72 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HIV-1 viral load from baseline to day 15</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate safety and tolerability</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>MPC-4326 200 mg BID X 14 Days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MPC-4326 300 mg BID X 14 Days.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevirimat dimeglumine</intervention_name>
    <description>Patients will be treated with MPC-4326 200mg monotherapy for 14 days. Once the Day 15 viral load results become available, patients, who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.</description>
    <arm_group_label>MPC-4326 200 mg BID X 14 Days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevirimat dimeglumine</intervention_name>
    <description>Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.</description>
    <arm_group_label>MPC-4326 300 mg BID X 14 Days.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years of age at the time of screening.

          -  Have HIV-1-infection.

          -  Have a CD4+-lymphocyte countâ‰¥100 cells/mm3

          -  Have a screening plasma HIV-1 RNA value, measured by the Roche Amplicor assay, of
             2,000 - 500,000 copies/mL (inclusive).

          -  Be free from any acute infection or serious medical illness within 14 days prior to
             study entry.

        Exclusion Criteria:

          -  Current opportunistic infection characteristic of AIDS (Category C according to the
             CDC Classification System for HIV-1 Infection, 1993 Revised Version, Appendix A) that
             is diagnosed within 30 days or is poorly controlled.

          -  Patients with systolic blood pressure &lt; 90 mmHg or &gt; 140 mmHg or diastolic blood
             pressure &lt; 60 mmHg or &gt; 90 mmHg.

          -  A history of seizures (excluding pediatric febrile seizures) or current administration
             of prophylactic anti-seizure medications.

          -  A history of cerebrovascular accident (CVA) or transient ischemic attacks (TIA).

          -  Patients with the following laboratory parameters within 30 days prior to first dose
             of study drug: Hemoglobin &lt; 10.0 g/dL for men and &lt; 9.0 g/dL for women Neutrophil
             count &lt; 1000/mm3 Platelet count &lt; 50,000/mm3 AST or ALT &gt; 2.5 times the upper limit of
             normal (patients with a positive HBV surface antigen or HCV antibody test at screening
             must have AST and ALT no more than 1.5 times the upper limit of normal)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Beelen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Myrexis Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIDS Research Initiative</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taylor Square Private Clinic</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2009</study_first_submitted>
  <study_first_submitted_qc>August 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2009</study_first_posted>
  <last_update_submitted>January 4, 2010</last_update_submitted>
  <last_update_submitted_qc>January 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Andrew Beelen, M.D., Study Director</name_title>
    <organization>Myriad Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

